Introduction to Optimal Neoadjuvant And Adjuvant Therapy For Patients With Early Tnbc
Exploring Optimal Neoadjuvant And Adjuvant Therapy For Patients With Early Tnbc reveals several interesting facts. Hope S. Rugo, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses
Optimal Neoadjuvant And Adjuvant Therapy For Patients With Early Tnbc Comprehensive Overview
Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, presents the results of KEYNOTE-522 (NCT03036488), ... Sarah S. Mougalian, MD, comments on the use of Lisa Carey, MD, FASCO, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the ...
Adam M. Brufsky, MD, PhD, FACP; Francisco Esteva, MD, PhD; Hope S. Rugo, MD; Lee Schwartzberg, MD, FACP; and Komal ...
Summary & Highlights for Optimal Neoadjuvant And Adjuvant Therapy For Patients With Early Tnbc
- Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, shares a summary of his talk on the
- Dr Ko Un Park, MD from Ohio State University comments on the use of systemic
- Peter Schmid, MD, PhD, FRCP, Barts Cancer Institute, London, UK, delivers an update on the Phase III KEYNOTE 522 study ...
- Lajos Pusztai, MD, DPhil, Yale School of Medicine, New Haven, CT, talks on the results of the Phase III KEYNOTE-522 ...
- Prof Arun speaks with ecancer at the 10th BGICC in Cairo about
Stay tuned for more updates related to Optimal Neoadjuvant And Adjuvant Therapy For Patients With Early Tnbc.
